Why Choose Private Prescription for Wegovy or Mounjaro?
Private vs NHS Route: Wegovy or Mounjaro or Ozempic Access Compared
The NHS route to weight management medications involves GP referral to specialist services, often requiring 6-month wait times and strict BMI criteria. Private prescription for Wegovy or Mounjaro eliminates these barriers entirely. While Ozempic remains licensed for diabetes treatment only, both Wegovy (semaglutide) and Mounjaro (tirzepatide) offer MHRA-approved weight management solutions through private clinics. EverydayMeds' streamlined process requires no GP involvement – simply complete our clinical assessment and receive expert prescriber review within 24-48 hours.
Private access ensures you receive the same genuine medications dispensed by NHS services, but without bureaucratic delays. Our GPhC-registered pharmacy (#9012878) sources authentic Novo Nordisk Wegovy and Eli Lilly Mounjaro directly, maintaining identical quality standards to hospital pharmacy supply. This approach particularly benefits patients whose BMI falls within treatment ranges but who face extended NHS waiting lists or complex referral requirements for specialist weight management services.
Wegovy vs Mounjaro vs Ozempic: Complete Pricing Breakdown
Understanding costs helps determine the most suitable option between Wegovy or Mounjaro through private prescription. Wegovy pricing starts with 0.25mg at £79.99 (after FIRST40 discount), progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg (£209.99). Our Intro Duo bundle combines 0.25mg and 0.5mg doses for £169.99, providing seamless transition through initial titration phases. Mounjaro pricing follows similar escalation patterns, with both medications requiring gradual dose increases over 16-20 weeks.
Bundle options offer convenience rather than savings – our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, eliminating multiple ordering requirements. Returning customers apply code DOSE25 at checkout, while new customers use FIRST40 to reach listed prices. Neither Wegovy nor Mounjaro requires upfront payment for entire treatment courses, allowing flexible monthly purchasing as tolerance and efficacy develop through prescribed titration schedules.
Clinical Evidence: Wegovy or Mounjaro Efficacy in Weight Management
The STEP clinical trial programme demonstrated Wegovy's efficacy across multiple patient populations, with STEP 1 showing approximately 15% average weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). STEP 2 focused on patients with type 2 diabetes, achieving approximately 9.6% weight reduction, while STEP 3 combined intensive behavioural therapy for approximately 16% average loss.
Mounjaro's SURMOUNT trials indicated similar efficacy patterns, though direct comparison between Wegovy or Mounjaro trials remains inappropriate due to different study designs and patient populations. Both medications work as prescription-only medicines requiring clinical supervision and lifestyle modification support. Individual results vary significantly, and clinical assessment determines which option – Wegovy or Mounjaro – suits specific medical circumstances and treatment goals.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones regulating appetite and glucose metabolism. This mechanism reduces hunger signals in brain appetite centres, promoting earlier satiety after smaller meals and potentially reducing food cravings throughout the day. Unlike Ozempic, which shares the same active ingredient but holds diabetes licensing only, Wegovy is specifically formulated and licensed for chronic weight management in adults with elevated BMI. The once-weekly injection schedule via FlexTouch pen device provides consistent medication levels, supporting sustained appetite control when combined with dietary changes and physical activity increases. Clinical effects typically develop gradually over 12-16 weeks as doses escalate from 0.25mg through to 2.4mg maintenance levels.
Ordering Process: Private Wegovy or Mounjaro Prescription Journey
EverydayMeds' streamlined process begins with a comprehensive 3-minute clinical assessment covering medical history, current medications, weight management goals, and contraindication screening for both Wegovy and Mounjaro options. Our prescriber team reviews submissions within standard 3 working days, or 24 hours via express service, determining the most appropriate medication and starting dose based on individual circumstances. Once approved, next-day delivery via cold-chain courier ensures temperature-controlled transportation maintaining medication integrity from pharmacy to your doorstep. All deliveries include injection guidance, dose escalation schedules, and 24/7 clinical support access. The prescription-only medicine status ensures every order receives individual clinical review, maintaining safety standards equivalent to NHS specialist services while eliminating referral delays and waiting list complications.
Storage and Practical Considerations: Wegovy or Mounjaro Management
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, though Wegovy offers superior travel flexibility with 6 weeks room temperature stability versus Mounjaro's 21-day limit. The FlexTouch pen system for Wegovy provides intuitive injection delivery, while Mounjaro uses KwikPen technology – both designed for weekly self-administration with minimal preparation requirements. Dose escalation protocols differ between medications, with Wegovy following a structured 16-week titration from 0.25mg to 2.4mg maintenance, while Mounjaro escalates over 20 weeks reaching higher maximum doses. Both prescription-only medicines require ongoing clinical monitoring and lifestyle modification support, with regular review appointments ensuring optimal treatment outcomes and side effect management throughout the weight management journey.
Private Prescription Advantages: Beyond Wegovy or Mounjaro Access
Private prescription services for weight management medications extend beyond simple medication access, providing comprehensive clinical support without NHS resource constraints. EverydayMeds' approach includes unlimited clinical consultations, dose adjustment guidance, and side effect management throughout treatment duration – services often limited within NHS specialist clinics due to patient volume pressures. Private access also enables flexible treatment switching between Wegovy and Mounjaro based on tolerance and efficacy, rather than rigid formulary restrictions common in NHS prescribing.
The private model particularly benefits professionals requiring discretional healthcare access, patients living in areas with limited NHS weight management services, or individuals whose treatment timeline doesn't align with NHS referral schedules. Clinical outcomes remain identical whether accessing Wegovy or Mounjaro privately or via NHS routes, but private prescription eliminates administrative barriers while maintaining identical medication quality and clinical oversight standards.
Start Your Weight Management Journey: Wegovy or Mounjaro Today
Both Wegovy and Mounjaro represent evidence-based approaches to medically-supported weight management, available through EverydayMeds' private prescription service without GP referral requirements or NHS waiting lists. New customers apply discount code FIRST40 at checkout, while returning patients use DOSE25 to access competitive pricing starting from £79.99 for initial Wegovy doses. Our clinical team determines the most suitable option – Wegovy or Mounjaro – based on your individual assessment, medical history, and treatment preferences. Complete your assessment today at everydaymeds.co.uk to begin your medically-supervised weight management journey with prescription-only medicines delivered directly to your door via temperature-controlled courier service.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
